Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
NCT01842841Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2013
- Primary completion
- Oct 2014
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velaglucerase alfa in Gaucher disease (GD), sponsored by Takeda. Primary endpoints: Number of Participants With Drug-related Adverse Events (AEs), Infusion-related AEs, and Serious AEs (SAEs), Number of Participants Using Concomitant Medication and 2 more. Started Mar 2013; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT01842841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842841.